AU2014236728B2 - Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides - Google Patents

Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides Download PDF

Info

Publication number
AU2014236728B2
AU2014236728B2 AU2014236728A AU2014236728A AU2014236728B2 AU 2014236728 B2 AU2014236728 B2 AU 2014236728B2 AU 2014236728 A AU2014236728 A AU 2014236728A AU 2014236728 A AU2014236728 A AU 2014236728A AU 2014236728 B2 AU2014236728 B2 AU 2014236728B2
Authority
AU
Australia
Prior art keywords
pla2g12a
amino acid
polypeptide
seq
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014236728A
Other languages
English (en)
Other versions
AU2014236728A1 (en
Inventor
Yang Li
Daniel C. H. Lin
Jinghong Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2014236728A1 publication Critical patent/AU2014236728A1/en
Application granted granted Critical
Publication of AU2014236728B2 publication Critical patent/AU2014236728B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01004—Phospholipase A2 (3.1.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
AU2014236728A 2013-03-15 2014-03-13 Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides Active AU2014236728B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361793503P 2013-03-15 2013-03-15
US61/793,503 2013-03-15
PCT/US2014/026736 WO2014151962A1 (en) 2013-03-15 2014-03-13 Method of treating metabolic disorders using pla2g12a polypeptides and pla2g12a mutant polypeptides

Publications (2)

Publication Number Publication Date
AU2014236728A1 AU2014236728A1 (en) 2015-09-24
AU2014236728B2 true AU2014236728B2 (en) 2018-09-13

Family

ID=50483573

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014236728A Active AU2014236728B2 (en) 2013-03-15 2014-03-13 Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides

Country Status (6)

Country Link
US (1) US9474792B2 (enExample)
EP (1) EP2968480B1 (enExample)
JP (1) JP6434485B2 (enExample)
AU (1) AU2014236728B2 (enExample)
CA (1) CA2906540C (enExample)
WO (1) WO2014151962A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2906540C (en) 2013-03-15 2021-01-12 Amgen Inc. Method of treating metabolic disorders using pla2g12a polypeptides and pla2g12a mutant polypeptides
WO2016040748A1 (en) 2014-09-12 2016-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for detection of smn protein in a subject and treatment of a subject
EP3263600A1 (en) 2016-07-01 2018-01-03 Université Claude Bernard Lyon 1 Inhibition of pla2r1 for the prevention and/or the treatment of type 2-diabetes
WO2020226450A1 (ko) * 2019-05-08 2020-11-12 경희대학교 산학협력단 포스포리파아제 a2를 유효성분으로 포함하는 비만 예방 또는 치료용 조성물
WO2021001377A1 (en) * 2019-07-02 2021-01-07 Fundacion Para La Investigacion Medica Aplicada cPLA2e INDUCING AGENTS AND USES THEREOF
AU2021225957A1 (en) * 2020-02-28 2022-09-08 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating SMN2
US20250235513A1 (en) * 2022-04-01 2025-07-24 The General Hospital Corporation Vectors and methods for the treatment of neurodegeneration, delaying cognitive decline, and improving memory

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012151159A1 (en) * 2011-05-02 2012-11-08 Ngm Biopharmaceuticals, Inc. Methods of modulating pla2g12a levels and treating disorders associated therewith

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
JP2002533119A (ja) * 1998-12-24 2002-10-08 ユニバーシティ カレッジ ロンドン グリコシルホスファチジルイノシトール特異的ホスホリパーゼｄタンパク質及びその使用
US20140099295A1 (en) * 2011-05-02 2014-04-10 Ngm Biopharmaceuticals, Inc. Methods of Treating Glucose Metabolism Disorders
CA2906540C (en) 2013-03-15 2021-01-12 Amgen Inc. Method of treating metabolic disorders using pla2g12a polypeptides and pla2g12a mutant polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012151159A1 (en) * 2011-05-02 2012-11-08 Ngm Biopharmaceuticals, Inc. Methods of modulating pla2g12a levels and treating disorders associated therewith

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MORGANE ROUAULT ET AL, "Novel Mammalian Group XII Secreted Phospholipase A 2 Lacking Enzymatic Activity + , +", BIOCHEMISTRY, (2003-10), vol. 42, no. 39, doi:10.1021/bi0349930, ISSN 0006-2960, pages 11494 - 11503 *

Also Published As

Publication number Publication date
US20160008439A1 (en) 2016-01-14
JP2016515123A (ja) 2016-05-26
EP2968480B1 (en) 2020-10-14
WO2014151962A1 (en) 2014-09-25
CA2906540C (en) 2021-01-12
EP2968480A1 (en) 2016-01-20
JP6434485B2 (ja) 2018-12-05
CA2906540A1 (en) 2014-09-25
US9474792B2 (en) 2016-10-25
AU2014236728A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
US20200325200A1 (en) Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US11739131B2 (en) Growth differentiation factor 15 (GDF-15) polypeptides
US20180000898A1 (en) Method of Treating or Ameliorating Type 1 Diabetes Using FGF21
US9474792B2 (en) Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides
DK2618830T3 (en) Formulations to a kvæggranulocytkolonistimulerende factor and variants thereof
HK1227723B (en) Use of il-22 dimer in manufacture of a medicament for intravenous administration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)